Key clinical point: Cancer drug prices are higher in the United States than in Europe, and they don’t correlate with clinical benefit in either region.
Major finding: Median cancer drug prices were 52% lower in Europe than in the United States. No association was found between the price differential and either American Society of Clinical Oncology Value Framework (P = .599) or European Society for Medical Oncology Magnitude of Clinical Benefit Scale (P = .321) scores.
Study details: An analysis of costs and value-related scores for 63 cancer drugs.
Disclosures: The study was funded by the Swiss Cancer League. The authors reported having no conflicts of interest.
Vokinger KN et al. ESMO 2019, Abstract 1631PD-PR.